2025-00851Notice

Secret Disease Meeting Announced With Maximum Transparency: None

Published Date: 1/15/2025

Notice

Summary

The National Institute of Allergy and Infectious Diseases is holding a closed meeting on February 12, 2025, to review important grant applications for clinical trials. This meeting affects researchers seeking funding for allergy and infectious disease studies and keeps sensitive information private. The decisions made could impact future research funding and medical breakthroughs.

Analyzed Economic Effects

2 provisions identified: 1 benefits, 0 costs, 1 mixed.

NIAID clinical trial grant review

If you are a researcher applying for clinical-trial grants, NIAID will review and evaluate those applications on February 12, 2025 from 11:00 a.m. to 2:00 p.m. The panel will consider Investigator-Initiated Extended Clinical Trial (R01, Clinical Trial Required) and NIAID Clinical Trial Implementation Cooperative Agreement (U01, Clinical Trial Required) applications, which can affect who receives research funding.

Meeting closed to protect confidentiality

The meeting on February 12, 2025 will be closed to the public under 5 U.S.C. 552b(c)(4) and 552b(c)(6). The closure is to protect confidential trade secrets or commercial property (such as patentable material) and personal information about people associated with the grant applications.

Your PRIA Score

Score Hidden

Personalized for You

How does this regulation affect your finances?

Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.

Free to start

Key Dates

Published Date
Effective Date
1/15/2025
2/12/2025

Department and Agencies

Department
Independent Agency
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register